Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia

Br J Haematol. 2017 May;177(3):486-491. doi: 10.1111/bjh.14066. Epub 2016 Apr 7.

Toby A Eyre¹, Christopher P Fox², Paneesha Shankara³, Richard Went⁴, Anna H Schuh^{1

5

6}

¹ Department of Haematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, UK.
² Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, City Campus, Nottingham, UK.
³ Department of Haematology & Stem Cell Transplantation, Birmingham Heartlands Hospital, Birmingham, UK.
⁴ Department of Clinical Haematology, The Rotherham NHS Foundation Trust, Rotherham, South Yorkshire, UK.
⁵ NIHR BRC Oxford Molecular Diagnostic Centre, Oxford University Hospitals NHS Trust and Department of Oncology, University of Oxford, John Radcliffe Hospital, Oxford, UK.
⁶ Department of Oncology, University of Oxford, Oxford, UK.

No abstract available

Keywords: TP53; B-cell prolymphocytic leukaemia; TP53 deletion; idelalisib; prolymphocytic leukaemia.

Publication types